346684-16-0

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 1-CYCLOHEXYL-5-(4-METHYLSULFANYL-PHENYL)-1H-PYRAZOLE-3-CARBOXYLATE is used as a pharmaceutical compound for its potential therapeutic properties. Its complex structure may allow it to interact with biological targets, offering new avenues for drug development and treatment of various diseases.
Used in Agrochemical Industry:
In the agrochemical industry, METHYL 1-CYCLOHEXYL-5-(4-METHYLSULFANYL-PHENYL)-1H-PYRAZOLE-3-CARBOXYLATE is used as a chemical component in the development of pesticides or other agricultural chemicals. Its unique structure may provide novel mechanisms for pest control or crop protection.
Used in Materials Science:
METHYL 1-CYCLOHEXYL-5-(4-METHYLSULFANYL-PHENYL)-1H-PYRAZOLE-3-CARBOXYLATE is utilized in materials science for its potential to contribute to the development of new materials with specific properties. Its complex molecular structure may enable the creation of innovative materials with applications in various industries.

InChI:InChI=1/C18H22N2O2S/c1-22-18(21)16-12-17(13-8-10-15(23-2)11-9-13)20(19-16)14-6-4-3-5-7-14/h8-12,14H,3-7H2,1-2H3

Upstream product

• 1778-09-2 4-(Methylthio)acetophenone 
• 24214-73-1 cyclohexylhydrazine hydrochloride 
• 346684-15-9 methyl (2Z)-2-hydroxy-4-(4-methylthiophenyl)-4-oxobut-2-enoate 

Downstream Products

• 640728-04-7 (1-cyclohexyl-5-(4-methylthiophenyl)pyrazol-3-yl)-N-methoxy-N-methylcarboxamide 
• 641640-06-4 [(4-{1-cyclohexyl-3-[4-(1,1,2,2-tetramethyl-1-silapropoxy)butanoyl]pyrazol-5-yl}phenyl)sulfonyl]methyl acetate 
• 641640-05-3 (4-{1-cyclohexyl-3-[4-(1,1,2,2-tetramethyl-1-silapropoxy)butanoyl]pyrazol-5-yl}phenylthio)methyl acetate 
• 641640-07-5 4-{1-cyclohexyl-3-[4-(1,1,2,2-tetramethyl-1-silapropoxy)butanoyl]pyrazol-5-yl}benzenesulfonamide 
• 640728-05-8 1-(1-cyclohexyl-5-(4-methythiophenyl)pyrazol-3-yl)-6-(1,1,2,2-tetramethyl-1-silapropoxy)hexan-1-one 
• 641640-04-2 1-{1-cyclohexyl-5-[4-(methylsulfinyl)phenyl]pyrazol-3-yl}-4-(1,1,2,2-tetramethyl-1-silapropoxy)butan-1-one 
• 640728-07-0 1-[1-cyclohexyl-5-(4-methanesulfonyl-phenyl)-1H-pyrazol-3-yl]-6-nitrooxy-hexan-1-one 
• 641640-03-1 1-[1-cyclohexyl-5-(4-methylthiophenyl)pyrazol-3-yl]-4-(1,1,2,2-tetramethyl-1-silapropoxy)butan-1-one 
• 640728-06-9 (1-Cyclohexyl-5-(4-(methylsulfonyl)phenyl)-pyrazol-3-yl)-6-hydroxyhexan-1-one 
• 641638-74-6 1-((3E)-4-(1-cyclohexyl-5-(4-methylthiophenyl)pyrazol-3-yl)but-3-enyloxy)-1,1,2,2-tetramethyl-1-silapropane 
• 641638-73-5 1-((3Z)-4-(1-cyclohexyl-5-(4-methylthiophenyl)pyrazol-3-yl)but-3-enyloxy)-1,1,2,2-tetramethyl-1-silapropane 
• 641640-08-6 4-[1-cyclohexyl-3-(4-hydroxybutanoyl)pyrazol-5-yl]benzenesulfonamide 
• 641639-52-3 1-(3-((1E)-4-(hydroxy)but-1-enyl)-1-cyclohexylpyrazol-5-yl-4-methylsulfonyl)benzene 
• 641638-75-7 1-(3-((1Z)-4-(hydroxy)but-1-enyl)-1-cyclohexylpyrazol-5-yl)-4-(methylsulfonyl)benzene 

Relevant academic research and scientific papers

Synthesis and Selective Cyclooxygenase-2 Inhibitory Activity of a Series of Novel, Nitric Oxide Donor-Containing Pyrazoles

The synthesis of a series of novel pyrazoles containing a nitrate (ONO 2) moiety as a nitric oxide (NO)-donor functionality is reported. Their COX-1 and COX-2 inhibitory activities in human whole blood are profiled. Our data demonstrate that py

Oxime and/or hydrozone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use

The invention describes novel cyclooxygenase 2 (COX-2) selective inhibitors having at least one oxime group or hydrazone group and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor having at least one oxime group or hydrazone group, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one COX-2 selective inhibitor having at least one oxime group or hydrazone group, optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention having at least one oxime group or hydrazone group can be optionally nitrosated and/or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal and/or respiratory toxicity; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.

Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use

The present invention describes novel nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitors and novel compositions comprising at least one nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or optionally, at least one therapeutic agent, such as, steroids, nonsteroidal antiinflammatory compounds (NSAID), 5-lipoxygenase (5-LO) inhibitors, leukotriene B4 (LTB4) receptor antagonists, leukotriene A4 (LTA4) hydrolase inhibitors, 5-HT agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) inhibitors, H antagonists, antineoplastic agents, antiplatelet agents, decongestants, diuretics, sedating or non-sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, Helicobacter pylori inhibitors, proton pump inhibitors, isoprostane inhibitors, and mixtures thereof. The present invention also provides novel compositions comprising at least one parent COX-2 inhibitor and at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The present invention also provides kits and methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 inhibitors; for facilitating wound healing; for treating and/or preventing renal toxicity; and for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2.